KKUR Stock Overview

Develops and provides proprietary cancer detection systems. More details

KKUR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap ($15K)

Latest financial reports are more than a year old

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

ChromoCure, Inc. Competitors

ThermoGenesis Holdings

OTCPK:THMO

US$1.6k

Sonendo

OTCPK:SONX

US$589.8k

LogicMark

NasdaqCM:LGMK

US$884.6k

Brain Scientific

OTCPK:BRSF

US$932.0k

Price History & Performance

Summary of share price highs, lows and changes for ChromoCure
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	0%
5 Year Change	0%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	KKUR	US Medical Equipment	US Market
7D	0%	0.09%	-0.3%
1Y	0%	7.7%	8.1%

Return vs Industry: KKUR underperformed the US Medical Equipment industry which returned 7.7% over the past year.

Return vs Market: KKUR underperformed the US Market which returned 8.1% over the past year.

Price Volatility

Is KKUR's price volatile compared to industry and market?
KKUR volatility
KKUR Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	9.7%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	4.2%

Stable Share Price: KKUR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine KKUR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	n/a	n/a

ChromoCure, Inc. develops and provides proprietary cancer detection systems. The company offers Chromosomal Scanner Series 200, a cancer detection system to measure the genomic characteristic found in 100% of all cancers and never found in normal cells. It also applies its science and technology to non-toxic and non-invasive approaches to cancer therapy and cure research.

ChromoCure, Inc. Fundamentals Summary

How do ChromoCure's earnings and revenue compare to its market cap?
KKUR fundamental statistics
Market cap	US$15.00k
Earnings (TTM)	-US$147.24k
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is KKUR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KKUR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$147.24k
Earnings	-US$147.24k

Last Reported Earnings

Dec 31, 2009

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did KKUR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/11 10:50
End of Day Share Price	2025/03/14 00:00
Earnings	2009/12/31
Annual Earnings	2009/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ChromoCure, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.